CellPoint Diagnostics

CellPoint Diagnostics is an early-stage company developing tools for cancer diagnosis, monitoring, and molecular analysis. Their novel proprietary technology captures and analyzes circulating tumor cells (“CTCs”) directly from patient blood. Scientific and clinical data have demonstrated that CTCs originate from primary tumors, and the evaluation of CTC numbers in blood has been shown to accurately predict survival rates in cancer patients. Their goal is to commercialize products that provide a safe, non-invasive “liquid biopsy,” delivering highly accurate, real-time, personalized clinical information about disease status and treatment response to doctors and patients. They aim to identify, diagnose, and guide treatment with specific drugs for lethal metastatic cancers. This has the potential to transform cancer from a fatal disease into a chronic condition and will become a powerful tool for developing new anti-cancer drugs.